Reference entry — NOT a sellable lane. Same status as semaglutide: an FDA-approved, patented blockbuster; compounded copies now largely prohibited. In the register for reference and completeness, not commerce. No dosing published here. Why the flagships sit in the register but not the shop — the ven
Tirzepatide is a dual GIP/GLP-1 agonist and, in the only head-to-head obesity trial (SURMOUNT-5), produced greater weight loss than semaglutide (−20.2% vs −13.7%). It is FDA-approved for type-2 diabetes (Mounjaro) and for obesity and obstructive sleep apnea (Zepbound), on a large Phase 3 base (grade A). Compounded copies are now largely prohibited following the December-2024 shortage resolution.
approved as Mounjaro (and Zepbound in the US; brand naming varies by market).
FDA-approved (Mounjaro / Zepbound; Eli Lilly only). Compounding: shortage declared resolved by the FDA (Declaratory Order, Dec 2024, all strengths); 503A enforcement discretion ended Feb 2025 → compounded tirzepatide now largely prohibited. Gray-market/counterfeit versions are unapproved and not FDA-reviewed.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026.
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.